Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Theophylline low-dose inhalation - Pulmagen Therapeutics

Drug Profile

Theophylline low-dose inhalation - Pulmagen Therapeutics

Alternative Names: ADC 4022; Theophylline Solution for Inhalation - Pulmagen

Latest Information Update: 19 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Argenta Discovery
  • Developer Argenta; Pulmagen Therapeutics
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Xanthines
  • Mechanism of Action Histone deacetylase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Mar 2014 Argenta has been acquired by Charles River Laboratories
  • 02 Feb 2010 Argenta Discovery has been acquired by Galapagos NV
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top